Steatosis and NASH in type 2 diabetes

Non Alcoholic Fatty Liver Disease (NAFLD) is currently the most common chronic liver disease in the world, encompassing various conditions ranging from simple steatosis, steatohepatitis, to fibrosis and cirrhosis. The association between NAFLD and Type 2 Diabetes (T2D) is strong and complex, given t...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Biochimie Ročník 143; s. 37 - 41
Hlavní autori: Hu, Mengyue, Phan, Franck, Bourron, Olivier, Ferré, Pascal, Foufelle, Fabienne
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: France Elsevier B.V 01.12.2017
Predmet:
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - physiopathology
dissociation
fatty acids
fatty liver
fibrosis
Hepatitis - etiology
Humans
Inflammation
Insulin Resistance
Lipotoxicity
NASH
Non-alcoholic Fatty Liver Disease - etiology
Non-alcoholic Fatty Liver Disease - metabolism
noninsulin-dependent diabetes mellitus
oxidative stress
Risk Factors
Steatosis
Type 2 diabetes
Type 2 diabetes
Insulin resistance
Inflammation
NASH
Lipotoxicity
Steatosis
ISSN:0300-9084, 1638-6183, 1638-6183
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Non Alcoholic Fatty Liver Disease (NAFLD) is currently the most common chronic liver disease in the world, encompassing various conditions ranging from simple steatosis, steatohepatitis, to fibrosis and cirrhosis. The association between NAFLD and Type 2 Diabetes (T2D) is strong and complex, given that the prevalence of NAFLD is particularly high in individuals with Type 2 Diabetes. In fact, insulin resistance occurring in this metabolic disease can promote NAFLD development, and vice versa, NAFLD can enhance insulin resistance. In this review, we focus on the mechanisms linking NAFLD and T2D, including fatty acid accumulation, inflammation, oxidative stress etc. We also discuss about situations showing a dissociation between steatosis and insulin resistance, in order to provide new insights for NAFLD therapeutic targets. •Steatosis and NASH are frequent among type 2 diabetic individuals.•In NAFLD patients, an increased dose of injected insulin is often necessary.•Insulin resistance promotes NAFLD through induced hepatic lipogenesis and adipose tissue lipolysis.•NAFLD enhances insulin resistance by inducing lipotoxicity, inflammation and ROS production.•Specific intrahepatic lipid species are important for alteration of insulin sensitivity.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0300-9084
1638-6183
1638-6183
DOI:10.1016/j.biochi.2017.10.019